Blood Biomarker Linked to Incident VTE in COVID-19 Patients
Higher levels of soluble urokinase plasminogen activator receptor linked to incident venous thromboembolism independently of D-dimer
Subject: Myocardial and Pericardial Disease
Cardiovascular Effects of Pre-Workout Caffeine and Energy Supplements
Gregory M Marcus, MD, MAS, and Jeffrey J. Hsu, MD, PhD, discuss the effect of caffeine and energy supplements on risk for cardiovascular events.
Substantial Post-Roe Risks for Patients With Cardiovascular Disease
Joseph M Truglio, MD, Ali N. Zaidi, MD, Monica V. Dragoman, MD, and Linda Cassar, DNP, RNC-OB, CNE, discuss the effect of the overturning of Roe v Wade on patients with CVD.
Provider Implicit Bias: Bringing Awareness to Clinical Practice
Implicit bias among health care providers factors into judgments and influences clinical decision making.
Spotlight on Increasing Myocardial Infarction Disparities in Young Women
Viola Vaccarino, MD, PhD, Yuan Lu, ScD, and Ersilia M. DeFilippis, MD, discuss increasing rates of myocardial infarction among young women.
Flow Cytometry-Based Method of Diagnosis Developed for Vaccine-Induced Immune Thrombotic Thrombocytopenia
Researchers sought to determine whether an assay using flow cytometry may help to diagnose patients who have vaccine-induced immune thrombotic thrombocytopenia.
Venous Thromboembolism Risk With COVID-19 in Patients With Sickle Cell Disease
Researchers sought to determine whether there was an increased risk of VTE in patients with SCD and COVID-19.
Novel Factor XI Inhibitor Fast Tracked for Thrombosis Associated With Cancer
Abelacimab is a highly selective, fully human monoclonal antibody designed to inhibit both factor XI and its activated form, factor XIa.
FDA Aims To Improve Medical Device Security
The agency has issued proposed draft recommendations to guide incorporation of cybersecurity protections into medical devices at the time of manufacture.
COVID-HEART Model Predicts Adverse Events in Hospitalized Patients With COVID-19
Investigators sought to develop and validate the COVID-HEART predictor to determine risk for adverse events in patients hospitalized with COVID-19.
- Loading...
Loading...
Next post in Thrombosis
Loading... 
Loading...